TunisiaTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (0.047–0.54) 2 (0.42–4.9)
Mortality (HIV+TB only) <0.01 (<0.01–0.01) 0.07 (0.05–0.09)
Prevalence  (includes HIV+TB) 4.6 (1.9–8.6) 42 (17–78)
Incidence  (includes HIV+TB) 3.7 (3.4–4) 33 (31–36)
Incidence (HIV+TB only) 0.023 (0.018–0.028) 0.2 (0.16–0.25)
         
Case detection, all forms (%) 84 (77–92)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.8 (0–1.7) 12 (4.5–19)
MDR-TB cases among notified pulmonary
TB cases
10 (0–22) 9 (3–14)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 052   34
Pulmonary, clinically diagnosed 214    
Extrapulmonary 1 834    
       
Total new and relapse 3 134    
Previously treated, excluding relapses 39    
Total cases notified 3 173    
Among 3 134 new and relapse cases:
195 (6%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 009 (96%) 43 (59%) 1 052
Laboratory-confirmed RR-/MDR-TB cases     14
Patients started on MDR-TB treatment ***     14
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 317 (73)
HIV-positive TB patients 12 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 12 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 54  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (91) 3 032
Previously treated cases, excluding relapse, registered in 2013 (86) 35
HIV-positive TB cases, all types, registered in 2013 (100) 17
RR-/MDR-TB cases started on second-line treatment in 2012 (73) 15
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 4.9
Drug susceptibility testing (per 5 million population) 1.8
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 1.3
% Funded domestically 57%
% Funded internationally 43%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-26 Data: www.who.int/tb/data